Orange Book product · Brand (NDA)
MICAFUNGIN IN SODIUM CHLORIDE 0.9%
MICAFUNGIN SODIUM
At a glance
Sep 29, 2023
Approved
Brand (NDA)
Application
Not listed
TE code
1
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 29, 2023
2 yr 9 mo ago
Today
Patent 12403173 expires
Listed drug product patent expiration.
Dec 15, 2037
in 11 yr 8 mo
Pharmaceutical detail
Active ingredient
MICAFUNGIN SODIUM
Strength
EQ 50MG BASE/50ML (EQ 1MG BASE/ML)
Dosage form
SOLUTION
Route
INTRAVENOUS
TE code
Not listed
Application
NDA 216142
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2021MICAFUNGINBrand (NDA)
NDA 212125 · TEVA PHARMS USA INC
- 2021MICAFUNGINBrand (NDA)
NDA 212156 · PH HEALTH
- 2005MYCAMINEBrand (NDA)
NDA 021506 · ASTELLAS
- 2026MICAFUNGIN SODIUMGeneric (ANDA)
ANDA 220296 · ASPIRO
- 2026MICAFUNGIN SODIUMGeneric (ANDA)
ANDA 219518 · YICHANG HUMANWELL
- 2026MICAFUNGIN SODIUMGeneric (ANDA)
ANDA 219712 · HISUN PHARM HANGZHOU
- 2025MICAFUNGIN SODIUMGeneric (ANDA)
ANDA 219273 · QILU PHARM HAINAN
- 2024MICAFUNGIN SODIUMGeneric (ANDA)
ANDA 216438 · BIOCON PHARMA
- 2022MICAFUNGIN SODIUMGeneric (ANDA)
ANDA 215241 · ZYDUS PHARMS
- 2022MICAFUNGIN SODIUMGeneric (ANDA)
ANDA 215381 · MEITHEAL
- 2021MICAFUNGIN SODIUMGeneric (ANDA)
ANDA 213261 · HIKMA
- 2021MICAFUNGIN SODIUMGeneric (ANDA)
ANDA 213363 · JIANGSU HANSOH PHARM
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 12403173 | Dec 15, 2037 | in 11 yr 8 mo | Product |

